ARTICLE | Product Development

Executing at Exelixis

Huge bet on XL184 in cancer depends on clinical trial execution by Exelixis

December 6, 2010 8:00 AM UTC

Deciding to use its limited cash to focus only on its most advanced clinical compound may have been the obvious choice for Exelixis Inc., especially after XL184 produced better-than-expected data in mid-November.

But while last week's headlines may have focused on the company's dramatic restructuring - it will eliminate 65% of its workforce over two years - the ability of Exelixis to become "The XL184 Company" ultimately is going to be all about clinical execution...